purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation nv earnings call period ending december image source motley fool novartis ag nv q earnings calljan etcontents prepared remark question answer call participant prepared remark operatorgood morning good afternoon welcome novartis q result release conference call live webcast please note presentation participant listenonly mode conference recorded operator instruction recording conference call including qa session available website shortly call end would like hand mr samir shah global head investor relation please go ahead sirsamir shah global head investor relation thank much good morning good afternoon everybody thank listening fullyear result q result information presented today contains forwardlooking statement involve known unknown risk uncertainty factor may cause actual result materially different future result performance achievement expressed implied statement description factor please refer company form f recent quarterly result form k respectively filed furnished yous security exchange commission hand across vasshould invest novartis ag right buy stock novartis ag consider motley fool stock advisor analyst team identified believe best stock investor buy novartis ag one stock made cut could produce monster return coming year stock advisor provides investor easytofollow blueprint success including guidance building portfolio regular update analyst two new stock pick month stock advisor service tripled return sp since see stock stock advisor return january va narasimhan chief executive officer thank samir thanks everyone joining today call know busy day many company reading hope provide insight q result also perspective outlook novartis beyond move first slide slide saw earnings release morning delivered strong fullyear performance margin expansion strong innovation momentum positive phase readout course reminder fullyear guidance start year quite bit lower ended multiple earnings upgrade course year demonstrating think strong business momentum company q sale core operating income full year sale core operating income constant currency harry go detail moment also successful spinoff sandoz really valuecreating event novartis shareholder provided updated guidance expect grow midsingle digit core operating expected grow high single digit chosen prudent guidance point time looking midterm guidance also go detail extended midterm guidance constantcurrency cagr growth continue hold core operating income margin guidance plus moving slide year really critical year company completed transformation novartis believe really laying strong foundation future growth since spun alcon sandoz shareholderfriendly way exited otc stake also shareholderfriendly approach exiting creating new otc company gsk also importantly exited roche stake completing billion share buyback continuing billion share buyback ongoing currently expect complete mid leaf u pureplay innovative medicine company margin way plus strong free cash flow strong innovation engine think position u well long run moving slide look q importantly underlying growth key growth driver grew overall quarter growth rate expect continue underlying growth give u confidence grow midsingle digit coming year continue growth beyond midsingledigitplus range combination growth driver well strong pipeline productivity put u think strong position consistent grower next decade moving slide want walk brand give perspective look forward taking question first entresto delivered growth sale reaching billion well track reach peak sale goal billion plus growth yous exyous geography see weekly trx continue reach record high constantcurrency growth yous ex yous china japan contributed strongly strong performance ongoing hypertension launch going looking forward expect continued growth brand maintain guidance forecasting purpose interest loe would occur also maintain guidance eu regulatory data protection november moving slide cosentyx reached billion expect see least mid highsingledigit growth way guidance billion peak sale going little deeper performance saw growth yous outside yous part yous due revenue deduction adjustment prior year leading lower base seeing good momentum iv hidradenitis launch yous hidradenitis europe give u confidence cosentyx dynamic grower coming year continue keep updated launch progress coming quarter quarter also keep updated well three ongoing phase study progressing giant cell arteritis pmr rotator cuff tendinopathy moving slide kesimpta sale full year doubled billion remain track reach billion peak sale guidance strong growth yous also increasing growth europe exyous market currently see patient treated cosentyx date yous growth constant currency ex yous nbrx leadership seven major market outside united state think everyone know well compelling profile term efficacy convenience well easytouse sensoready pen patient benefit kesimpta five year efficacy safety tolerability look forward continuing expand brand term growth bcell class m also increasing nbrx share within bcell class key growth driver moving slide kisqali reached billion metastatic breast cancer setting maintain billion peak sale guidance metastatic breast cancer setting alone see growth driven yous international business rolling nbrx share metastatic setting see continued strong growth metastatic setting driven statistically significant o across three pivotal study nccn category designation median o five year demonstrated across three pivotal trial confirm filed eu yous china adjuvant indication across intermediate highrisk breast cancer look forward keeping speed progress toward hopefully approval launch course year moving slide pluvicto fullyear sale closeout near blockbuster status million importantly see unconstrained supply brand maintain multibillion dollar peak sale guidance current indication say see strong demand signal growth dynamic january consistent expectation cleared supply constraint challenge saw quarter would get back strong robust growth quarter would expect robust quarteronquarter growth course year detail term treatment site yous site active regularly ordering fully unconstrained supply dos injected planned day capacity radioligand therapy dos expected approval indianapolis site network expansion ongoing prepare launch asia announced investment china japan already noted expect robust quarteronquarter growth course psmafore expected yous submission secondhalf keep updated progress toward also remain track psmaddition psma localized oligometastatic disease trial move pluvicto earlier line therapy moving slide scemblix strong year strong quarter moving million quarter thirdline setting leading thirdline market share actually share trx share think well know high unmet need thirdline setting hematologist really want improvement quality life better management side effect scemblix really delivers four year followup really demonstrated differentiated profile term efficacy well clear strong safety profile global rollout thirdline setting ongoing approval market access granted market positive feedback payer clinical benefit moving slide read earlier month ascfirst trial met primary endpoint clinically meaningful statistically significant result frontline setting scemblix reminder study scemblix compared investigatorchoice tki estimate patient imatinib patient secondgen tkis nilotinib dasatinib bosutinib primary endpoint met showed superior major molecular response rate week versus standard care also favorable safety tolerability profile fewer aes treatment discontinuation new safety signal observed excited data importantly mmr good predictor reasonable predictor important endpoint pfs o efs data presented upcoming medical congress moving rapidly toward submission first half look forward sharing full data set really providing conviction scemblix multibillion dollar medicine novartis moving slide leqvio continued steady expansion yous well across region see delivered million quarter growth international yous business yous side facility ordering leqvio growth versus quarter business coming inoffice buy bill expect continue drive growth brand driving depth key account well expanding buy bill acquisition channel ex yous rollout also continues well country public reimbursement country private coverage see positive solid early signal china selfpay market expect continue course ahead proposed nrdl listing term outcome trial remain track secondary prevention outcome study also continue enroll primary prevention study well moving slide fabhalta launched united state see think positive early launch signal expect modest ramp brand given dynamic within pnh market reminder compelling data medicine including improvement hemoglobin transfusion avoidance ivh intravascular extravascular hemolysis control clean safety profile population label adult pnh naive switch patient target label medicine oral therapy think really provide unique offering patient pnh rem requirement similar complement inhibitor right look launch focus much coming ash getting patient patient support program getting rem running first patient already initiated hearing positive hcp sentiment interest patient payer group goal initially focus newly diagnosed patient well patient currently full control hemolysis existing therapy time would want certainly expand market estimate half patient pnh currently therapy oral agent possibility hope time get patient therapy avoid subsequent sequela associated pnh moving slide noted positive phase readout significant sale potential see listed lot data presented course better understanding potential medicine whether medicine like remibrutinib already seen lutathera netter data think really outstanding hopefully saw potential lutathera frontline setting course data atrasentan iptacopan scemblix data already mentioned moving slide want say word topline readout quarter iptacopan another third phase readout positive phase readout clinically meaningful statistically significant proteinuria reduction patient cg glomerular nephropathy see left phase data previously disclosed phase study design versus placebo looking month six patient crossed iptacopan arm saw really important proteinuria reduction safety profile consistent seen previous data currently engaged regulatory agency goal submission moving slide course year positive readout iptacopan newly acquired atrasentan iga nephropathy clinically meaningful result well program reviewed fda track submission medicine would really allow u think robust portfolio medicine bring nephrologists iga nephropathy future cg continue try build nephrology presence around world zigakibart antiapril antibody also acquired chinook acquisition also track phase study moving slide expect innovation momentum continue year data readout full data readout submission primarily company expect phase start importantly mentioned key data readout submission keep posted progress look slide confidence well steady stream innovation drive company growth beyond number exciting think asset well timeframe create steady flow replacement power innovation enabling u drive midsingledigit growth rate beyond moving slide course year also signed strategic deal exit well acquisition totaling billion want emphasize core approach remains bolton acquisition sub billion space deal chinook also many smaller deal see across full landscape much focused technology like xrna gene therapy rlt well key therapeutic area like chinook among others also continue invest artificial intelligence top collaboration microsoft palantir also signed agreement isomorphic lab google deepmind really allows u think partnered preeminent ai researcher world speed drug discovery drug development moving slide also today extend update midterm guidance remember rd day noted cagr today given momentum seeing growth driver strong pipeline performance seeing extending growth guidance course gx impact sure discus qa momentum seeing inmarket growth driver across base business across brand already discussed well positive data seen fabhalta remibrutinib atrasentan give u confidence continue growth already guided midsingle digit beyond moving slide want close word esg remains much part novartis strategy novartis approach focus innovation access medicine human capital term work dei culture well ensuring among leader environmental sustainability ethical standard look performance sustainalytics leader group msci also among leader important benchmark access medicine cdp plan continue course slide hand harryharry kirsch chief financial officer yeah thank much va good morning good afternoon everybody going walk financials fourth quarter full year well provide guidance always comment refer growth rate constant currency unless would otherwise note also throughout presentation going talk continuing operation reminder continuing operation include retained business activity novartis comprising innovative medicine business continued corporate activity discontinued operation include sandoz selected portion corporate activity attributable sandoz business well certain expense related spinoff next slide please chart show restated comparable number post sandoz spinoff know history tell future track record important see since topline sale growth average bottom line even cagr resulted core margin increase basis point constant currency clear path also margin standpoint strong performance continued met even slightly exceeded upgraded fullyear guidance next slide yeah little comparison show topline growth guided grow basically high single digit last one upgraded three time year started low midsingle digit really testimony excellent business momentum even strengthened throughout year core operating income could able upgrade three time could even slightly exceed guidance gave october mid high teen slide bit detail performance go quarter full year quarter topline growth core operating income grew outlook october quarter highprofit quarter compared given middle restructuring guided full year already assuming quarter bottomline growth would little bit le ninemonth bottomline growth still resulting margin improvement percentage point core eps good quarter full year top line grew core building income delivered leading point margin increase core eps fullyear cash flow even billion another significant growth also cash flow side outlook therefore guidance strong fullyear result also strong quarter absolute course comparable base bit higher slide continuing create significant sustainable shareholder value know highly cashgenerative business strong cash flow allows u optimize investing business well returning capital shareholder term investing business course rd key focus addition launch prelaunch investment business development business development perspective valuecreative boltons core therapeutic area term returning capital shareholder focus consistent growing annual dividend swiss franc rebased post alcon sandoz spinoffs regard share buyback continue course recent share buyback billion announced july billion executed still end got question paused share buyback week january adjust trading plan ensure everybody clear restart next day full intention complete share buyback mentioned end besides course also created shareholder value numerous strategic action like divesting consumer healthcare joint venture stake spinning alcon divesting roche stake chf million course importantly recently successful completion spinoff sandoz october last year go next slide please talking successful spinoff sandoz day spinoff subsequently novartis well sandoz share price implied market capitalization increased quite significantly since day spinoff october yesterday exact number last night closing novartis market cap increased sandoz total result spinoff course subsequent market movement combined value billion created shareholder continuing hold novartis sandoz share reminder rebasing dividend post sandoz spin speaking dividend let u go next page yes pleased propose th consecutive dividend increase chf per share yous dollar even based chf franc last year increase swiss franc yous dollar dividend yield reaching close fully line policy increasing dividend every year swiss franc per share without rebasing post sandoz spin moving fullyear guidance sale grow midsingle digit core operating income grow high single digit term driver core op inc push pull similar fully expect positive business momentum continue however prudent guidance assumes higher generic impact versus sure discus later qa forecasting purpose assume yousinterested generic entry complete fullyear guidance please note expect core net financial expense around billion billion core tax rate around onto final slide go currency yes outlined detail regarding currency impact see currency negative point impact net sale quarter full year well negative point impact core operating income quarter negative point full year driven strong swiss franc special effect core op inc quarter right point due middecember argentina devaluation catch basically due hyperinflation accounting instruction ifrs guideline full effect quarter point worsening due argentina quarter late january rate prevail expect fullyear impact currency le top line would negative bottom line would negative currency impact reminder update every month website hard forecast outside get monthly update hand back vasvas narasimhan chief executive officer great thank harry conclusion go slide strong multiple guidance increase doubledigit growth sale core op inc think really reflecting focused strategy pureplay innovative medicine company right one really delivering strong operational performance met exceeded strategic operational innovation target including successful sandoz spinoff positive phase three readout significant sale potential confident midterm guide constantcurrency sale plus margin building course longerterm goal maintain midsingledigit sale growth beyond open line question operator instruction thank much question answer operatorthank operator instruction go first question first question come line matthew weston ubs please go aheadmatt weston ubs analyst thank much matt weston ubs one question around growth sga saw q mean guidance significant stepup commercial spending va mentioned opening remark felt guidance prudent q stepup bringing forward frontloading launch spend given exciting opportunity level good indicator cost acceleration expect full year help gratefully receivedvas narasimhan chief executive officer thanks matthew hand harry harryharry kirsch chief financial officer hello matthew good around think quarter came exactly forecasted year outlined fullyear guidance october think keep bit perspective overreact shortterm consensus thinking end increased function cost full year like constant currency growth top line tried explain maybe successful october quarter lowspend quarter middle big restructuring quarter spend usual seasonality higherspend level versus first three quarter bit muted back normal pattern worry cost development guidance continued margin improvement absolutely bulletproof topline growth well productivity program everything came plannedvas narasimhan chief executive officer thank youmatt weston ubs analyst many thanks indeedvas narasimhan chief executive officer thank matthew next question operatoroperatorthank next question come line andrew baum citi please go aheadandrew baum citi analyst hi sure dave call someone might like take question relating cardiovascular outcome trial previously asked unblind orion particularly given pressure ira nine year prior price negotiation would ask question horizon highrisk secondary prevention patient know highly arthrogenic particle got issue nine year possibility either trial unblinded publicly stated date maybe could also opine whether bipartisan effort try reclassify advanced therapy year rather nineyear exclusivity going start move obviously relevant given leqvio pelacarsen pluvicto etc many thanksvas narasimhan chief executive officer yeah thank andrew right plan adjust thought process waiting study run completion think dave outlined rd day continue believe longer followup likely deliver differentiated cardiovascular risk reduction orion think respect horizon powering calculation approach taken highrisk lpa patient well kind mediumrisk patient requires u follow patient said cognizant point debate discus especially light ira think thing first policy front bipartisan support amendment think socalled genetically targeted therapy however think still sometime likely year given election year really move forward hopeful progress coming year enable move along broader policy goal industry move across small molecule also continue invest lifecycle management entire sirna portfolio struck least deal really target annual dosing sirnas recently company called atlantic therapeutic multiple target pursuing try move annual dosing andor combination target would allow u lifecycle manage event need ahead nineyear timeframe approach taking obviously take feedback seriously continue evaluate accordingly next question operatoroperatorthank next question come line florent cespedes societe generale please go aheadflorent cespedes societe generale analyst good afternoon thank much taking question quick one midterm guidance dated guidance starting higher base wondering anything new versus last update end last year see let u say new driver would help achieve midterm guidance thank youvas narasimhan chief executive officer yeah thank florent think thing first term growth driver overall saw quarter quarter full year see dynamic growth kesimpta kisqali think strong growth lutathera scemblix also saw return mentioned strong demand signal pluvicto gave u confidence brand outlook toward peak sale guidance addition approval iptacopan iptacopan positive fabhalta positive data across pnh cg igan give u conviction medicine multibilliondollar medicine well think positive side inline brand importantly scemblix firstline data saw think really believe potentially practicechanging data opportunity well multibillion dollar medicine taking together growth momentum inline brand strong pipeline performance gave u conviction longterm guide would also note course kisqali also filed medium highrisk woman early breast cancer think give u positive signal momentum continue plus guidance florent cespedes societe generale analyst thank muchvas narasimhan chief executive officer next question operatoroperatorthank next question come line graham parry bank america please go aheadgraham parry bank america merrill lynch analyst great thanks taking question pluvicto number quarter drop quarter quarter think instead q would actually seen increase patient start also offsetting factor sicker patient getting sort last two dos help u dynamic increase patient saw q translate higher sale number q site think would said many targeting given supply unconstrained actually ratelimiting step getting multibillion number talked vision indication thank youvas narasimhan chief executive officer yeah thanks graham pluvicto quarter saw steady rebuild think see yet full replenishment base patient given still supply constraint august well july august timeline course quarter saw patient getting therapy course give u four six dos patient build base would also say holiday period see le expecting christmas period thanksgiving period patient tend want therapy given radiation lead lead restriction around child loved one think dynamic play role see growth new patient start q versus q growth think strong maybe external world predicted tried guide quarter expectation would rounded billion exactly million mark perhaps clear outlook expectation said course track daily basis see strong growth demand strong overall dynamic continue expect see robust quarteronquarter growth pluvicto course year getting u back toward multibilliondollar outlook guided vision populationgraham parry bank america merrill lynch analyst centersvas narasimhan chief executive officer center sorry graham yes goal get plus center expanding rapidly think center probably one constraint think term growth expect add center steady clip course year also encouraging physician supply unconstrained treat earlier therefore average number patient move toward six dos per patient certainly goal course year think dynamic fuel growth brand course graham parry bank america merrill lynch analyst thank youvas narasimhan chief executive officer thank graham next question operatoroperatorthank next question come line john priestner jp morgan please go aheadjohn priestner jpmorgan chase company analyst hi thank much taking question said guidance includes impact generic assume kind promacta also tasigna thinking behind actual timing generic entry also also said guidance could somewhat prudent key kind lever could execute kind exceed guidance thank youvas narasimhan chief executive officer yeah thanks john three generic entry would expect course year position think provide specific guidance entry would happen given think unpredictability term goal defend ip well supply party three would promacta tasigna noted well sandostatin lar approved generic product market course would provide update would enter course year think current forecast see course thing evolve term fullyear performance harry term prudent guidanceharry kirsch chief financial officer yeah john thank much mean say assume right financial forecast assumption course appropriately defend ip possible course sandostatin lar ip anymore ability generic producer produce difficulttoproduce product hand already distributed three potential entry forecast purpose quarter bit generic portfolio play come bit later may upside guidance meant course overall assume key growth driver continue perform well bit difficult three different generic make assumption prudent way could change either one competitor produce upside loe patent defense twojohn priestner jpmorgan chase company analyst good thank youvas narasimhan chief executive officer next question operatoroperatorthank next question come line tim anderson wolfe research please go aheadtim anderson wolfe research analyst thank cosentyx question pricing market access dynamic yous multisource biosimilar humira market albeit six seven month seeing access tightening step edits given indication overlap think might tighten also topic level yous net price erosion relative last yearvas narasimhan chief executive officer yeah thanks tim term cosentyx actually feel pretty good overall access environment modest growthtonet shift overall broader access major account versus past seen let u call increased impact biosimilar adalimumab think mostly contracting within ila class given track record class large position enabling u manage overall access environment successfully seen knowledge increase step edits either respect cosentyx access think looking forward obviously always difficult predict think tailwind going u new indication hidradenitis course least one medicine indication give u strength term formulary negotiation hopefully indication come well separate well cosentyx launched iv setting well also another think important growth driver medicine coming year overall think pretty stable position cosentyx least course understand better beyond keep everybody updated moving next question thanks timoperatorthank next question come line simon baker redburn please go aheadsimon baker redburn partner analyst thank taking question another one cosentyx wonder could give u thought expectation uptake cosentyx h client suggesting slower expected given quality profile paucity competition potential uptake course next year thanks muchvas narasimhan chief executive officer yeah thanks simon mean think early day think want think get far ahead far heard positive feedback overall clinician mean cosentyx outstanding longterm safety profile think well established many many year safety topic competitor may think allows u strong comfort level dermatologist treating patient well overall efficacy think solid opportunity give patient safe efficacious option know big challenge h really getting patient come treated given long since new medicine launched since tnf indicated condition think solid early start certainly see quarter unfolds think safety profile overall comfort level dermatologist give u good position launchsimon baker redburn partner analyst great thank youoperatorthank next question come line kerry holford berenberg please go aheadkerry holford berenberg capital market analyst oh thank couple question please firstly kisqali expect drug become eligible price negotiation ira given moving toward think patent expiry talk lifecycle management option available look novartis pipeline see breast cancerspecific asset perhaps wrong feedback could give area interest would gratefully received business development clearly somewhat busy last month appetite deal moving size therapeutic category rlt still area focus business development many thanksvas narasimhan chief executive officer thanks kerry first kisqali know precise science predict ira patient would also note early breast cancer population patient younger tend medicare population would say really see topic kisqali toward end decade importantly would affect portion sale medicare population course learn understand better program unfold keep updated think good runway medicine coming year metastatic assuming approval early breast cancer space term lifecycle management breast cancer course one opportunity cdk target pursuing house something looking within research lab well potential combination another topic u well also continue advance early stage program rlts breast cancer well specifically lifecycle management kisqali would give u opportunity bring forward radioligand therapy breast cancer space area high focus u moment think combination novel target small molecule well radioligand therapy breast cancer overall breast cancer space term business development outlined slide strategy much focus four core therapeutic area three key technology platform technology platform cell therapyimmune reset cell gene therapyimmune reset rlt rna therapeutic think well known term size deal change overall approach smaller billion bolton acquisition vast majority deal sub billion deal change approach previously stated moving nextoperatorthank next question come line seamus fernandez guggenheim security please go aheadseamus fernandez guggenheim partner analyst thanks much wanted ask one particular question term sort business development strategy know va already talked wanted get little bit clarity specific around sort threshold talked publicly sort billion threshold really still kind target range given success seeing area development opportunity potentially go larger term potential transaction wanted get better sense feel flexibility given phase solid phase hit rate kind sticking gun knitting billion south rangevas narasimhan chief executive officer thanks seamus really nothing think add beyond already stated course look full range would expect company size full range potential opportunity within business development consistently see opportunity significant opportunity value creation well differentiated view versus market lower end range deal value think look plus deal last year vast majority billion even million chinook billion think see best opportunity u company never exclude would anything make sense shareholder make sense longterm profile novartis focus much bolton sub billion sub billion billion range program think moving next question thanks seamusoperatorthank next question come line emily field barclays please go aheademily field barclays analyst hi thanks taking question question remibrutinib far along recruitment m trial given seen another partial clinical hold space could remind u molecule differentiated given see phase failure rd day thank youvas narasimhan chief executive officer yeah thank thanks emily remibrutinib let start think molecule differentiated look structure go back slide rd day see molecule different overall chemotype structure peer believe liver signal seen thus far group medicine offtarget toxicity related structure molecule highly potent btk inhibitor covalent btk inhibitor think unique least far clinical preclinical work profile term offtarget toxicity course already read two positive phase study csu plan file week data second half year continue pursue well remibrutinib immunology indication think opportunity given safe profile importantly dose range milligram bid saw liver signal dermatology study term m trial continue recruit track however expect filing mistaken futility analysis looking futility noninferiority comparator passed futility analysis program continue see safety signal passed futility analysis put place given data peer read continue progress study multiple sclerosis well believe remibrutinib opportunity significant medicine across range indication particularly safety profile continues hold structure medicine thanks emily next question operatoroperatorthank next question come line peter welford jefferies please go aheadpeter welford jefferies analyst hi thanks taking question curious wanted come back fabhalta iptacopan sort cautious commentary perhaps might expect new launch wonder could talk little bit say relate specifically pnh market perhaps perhaps confident potentially get currently untreated patient sooner reflect rem initial program perhaps impediment seeing getting front doctor process perhaps envisaged guess profile drug read potential rollout larger igan indication potentially future thank youvas narasimhan chief executive officer yeah thanks peter first pnh much uptake much rem well element need placed particularly vaccination take time put place medicine well organization getting infrastructure fully running estimate patient pnh united state roughly treated today ultrarare patient population well relatively high dispersion physician treating one two patient also take time reach physician change longterm belief become medicine choice patient given twiceaday safe oral medicine high efficacy think reasonable safety profile overall take time get physician speed either patient position need switch uncontrolled time even controlled patient would argue would want switched new start well make effort already try reach half estimated half patient population currently untreated want set reasonable expectation first year hope ramp thereafter think given positioning cg igan cg already also ultrarare disease igan target refractory patient given targeting select patient population think absolutely manage patient start process patient ensure strong uptake medicine look future indication fabhalta largely also ultrarare space think build capability able get patient therapy sustainably time thanks peter next question operatoroperatorthank next question come line richard parkes bnp paribas please go aheadrichard parkes exane bnp paribas analyst hi thank taking question following business development strategy mean quite clear last month confident growth upcoming loes business overall still absorb loes specific therapeutic category thinking entresto look cardiovascular franchise given leqvio may bit slower pelacarsen still clinical risk comfortable got enough coming inaudible maintain healthy franchise kind negative leverage post area would look maybe active term business development bring laterstage product thank youvas narasimhan chief executive officer yeah thanks richard feel confident inhouse cardiovascular disease look leqvio secondary prevention moving primary prevention well pelacarsen lpa program program called xxb currently moving forward midstage study hypertension heart failure well oral version xxb well npr agonist also bringing forward noted extensive inhouse sirna effort targeting range lipidlowering cardiovascular target well external collaboration also brought board think allows u cover key target would interest sirnas goal one move new target two move combination three also get annual dosing think right strategy cardiovascular disease long run course company pursuing oral fully understand believe space given compliance challenge long run demonstrated decade infrequently administered sirnas validated target right strategy given effort ongoing feel comfortable internal cardiovascular portfolio pipeline next question operatoroperatorthank operator instruction next question come line mark purcell morgan stanley please go aheadmark purcell morgan stanley analyst yeah thanks taking question kesimpta va hopefully help u understand growth dynamic mbx leadership mean especially light exyous acceleration think bcell nbrx share exyous share compare yous get data roche look nbrx leadership footnote seven market said data file could help u understand guess infusion barrier treatment exyous market versus yous share stand relative alternative infused therapy space housekeeping kisqali natalee filing include negative patient filing thanks muchvas narasimhan chief executive officer yeah thanks mark kisqali yes negative patient included kesimpta first exyous dynamic think first important note outside yous structure part b providing infused medicine many healthcare system preference move patient medical center medical home athome therapy key market really see dynamic know specific share offhand see dynamic favored class medicine large exyous market strong performance market like germany strong performance market like japan think really reflection different dynamic market preference neurologist provide patient medicine easy athome use hope time move kesimpta broadly across europe asia opportunity drive significant growth ex yous yous different dynamic right estimate bcell class share nbrx mid range time expect continue grow kesimptas share within bcell class high depending look right growing bcell class overall much goal time grow share bcell class something much focused take think time u achieve going important want get well beyond billion guidance already given think get billion march bcell class want better need improve bcell class share yous something definitely focused onrichard parkes exane bnp paribas analyst thank youvas narasimhan chief executive officer next question operatoroperatorthank next question come line stephen scala td cowen please go aheadsteve scala td cowen analyst thank much curious happens entresto ira price negotiation generic launch would seem entresto generic entresto would eligible price negotiation see come price negotiation far yes best case would seem novartis would limited generic competition maybe even unauthorized could turn plus entresto revenue thank youvas narasimhan chief executive officer yeah thanks steve valid point position would generic launched medicine portfolio per current guidance ira would eligible point time would view think know many thing still unfolding respect ira negotiation obviously comment approach various generic entrant approach manage would say look entresto even beyond yous guide mid loe ira move generic enter would iraeligible early one way another going entresto impacted period time important note guide plus growth even entresto coming yous also coming europe given timeline rdp europe think feel confident grow well beyond entresto loe ira however ultimately happens period next question operatoroperatorthank next question come line matthew weston ubs please go aheadmatth weston ubs analyst thank much thanks taking followup followup pluvicto va think jpmorgan rd day highlighted psmafore filing second half give u update anything changed also give u update discussion regulator know lot discussion modeled control arm given significance crossover give investor comfort still confident acceptable fda regulator around worldvas narasimhan chief executive officer yeah thanks matthew update trial continues accrue event mean based current estimate think secondhalf filing right timeline provide point time course evolve event accrue term confidence level nothing changed look overall data set saw last year saw impressive gain pfs saw impressive gain orr saw high quality life improvement relatively clean safety profile even versus arpi comparator arm think positive safety profile overall think compelling case think really matter getting higher resolution term adjusted analysis already hazard ratio well tighter radius around allcomers analysis well o course topic discussion fda think make clear compelling case medicine offered patient pretaxane setting also continuing mentioned move forward rapidly psmaddition well pluvicto oligometastatic setting cover base think overall industry learn upcoming ad coms competitor medicine fda thinking o crossover manage hopeful overall patient benefit ultimately rule statistical pure statistical consideration given encouraged utilize crossover study patient friendly appropriate way think important start looking adjusted analysis otherwise put overall industry challenging position next question operatoroperatorthank next question come line graham parry bank america please go aheadgraham parry bank america merrill lynch analyst ok thanks taking followup wanted dig moving part guide generic sort made sort highlevel comment term ability manufacture seen sandostatin lar think gotten approval restriction legal one litigation around manufacturing even around approval tech ops consideration promacta believe litigation outstanding sole patent moving part timing launch launch promacta even also still possibility thank youvas narasimhan chief executive officer yeah thanks graham sandostatin litigation ongoing think comment company manufacturing capability think observe europe launch generic limited supply available launch given complexity manufacturing believe complexity well would still case yous difficult medicine consistently make characterize release obviously approved generic ultimately determine monitoring see product come market volume meantime well mean much focused lutathera frontline data think presented really compelling data make lutathera medicine frontline medicine choice already onlabel already promoting physician making sure physician understand dataset generated net two fact opportunity well maintain neuroendocrine tumor business respect promacta much add course continue defend ip try maintain medicine protection long possible point time provide detail guidance promacta forecasting purpose staying generic entry always defend ip fullest extent possible moving last question operatoroperatorthank last question today come line tim anderson wolfe research please go aheadtim anderson wolfe research analyst thank much obesity think asked quite possibly biggest therapeutic category guy big presence cardiometabolic high priority enter space acquirable asset clinical development fall sub billion range move one lateentrant product still capture revenue vulnerability far ahead justify cost competitive development programvas narasimhan chief executive officer yeah thanks tim look think obesity market much look lens presence cardiovascular disease wanting ensure presence enables future cardiovascular drug pipeline either combinable available patient full range cardiovascular disease certainly something evaluating looking current view given number company already pursuing injectable oral glp gip top asset focused differentiated asset novel target novel approach novel profile look research course evaluate opportunity currently given size market importance cardiovascular health obviously find something interest pursue moment really say anything specific anything looking perfect thanks everyone joining look forward keeping updated course year wish everyone great operatoroperator signoff duration minutescall participantssamir shah global head investor relationsvas narasimhan chief executive officerharry kirsch chief financial officermatt weston ubs analystandrew baum citi analystflorent cespedes societe generale analystgraham parry bank america merrill lynch analystjohn priestner jpmorgan chase company analysttim anderson wolfe research analystsimon baker redburn partner analystkerry holford berenberg capital market analystseamus fernandez guggenheim partner analystemily field barclays analystpeter welford jefferies analystrichard parkes exane bnp paribas analystmark purcell morgan stanley analyststeve scala td cowen analystmatth weston ubs analyst nv analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy